ReviewAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2019
Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.
Review in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Psychosocial and Demographic Factors Associated with Physical Multimorbidity in Severe Mental Illness: A Systematic Review.Schizophrenia bulletin · 2026Pooled it
- Genetic correlation and causal relationships between autoimmune thyroid disease and major depressive disorders.Acta neuropsychiatrica · 2025Pooled it
- Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis.Schizophrenia bulletin · 2021Pooled it
- Gender differences in working memory impairment and metabolic characteristics among patients with stable schizophrenia: a cross-sectional study.European archives of psychiatry and clinical neuroscience · 2026Article
- Smoking and its associations with metabolic indices, clinical symptoms, and cognitive functioning in schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Mapping genetic convergence across brain structure, mental health, and cardiometabolic disease.Communications medicine · 2026Article
- Association of metabolic syndrome with comorbid major depressive disorder in remitted schizophrenia: a cross-sectional study.BMC psychiatry · 2026Article
- Secondary analysis of GenRED data (Genetics of Recurrent Early-Onset major Depression) using MERLIN.European archives of psychiatry and clinical neuroscience · 2026Article
- Diagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study.BMC psychiatry · 2026Article
- Unraveling the genetic interplay and therapeutic potentials between major depressive disorder and metabolic syndrome: multi-ancestry and multi-trait genome-wide association analyses.BMC psychiatry · 2026Article
- Within and beyond the boundaries of proteasomal assembly: PSMD9 chaperone as a multifunctional protein.Essays in biochemistry · 2025Review
- A retrospective and comprehensive analysis of excess life-years lost, mortality risk, and cause of death among severe mental illness in China.BMC medicine · 2025Article
- The Pathobiological Underpinnings of Psychosis: From the Stress-Related Hypothesis to a Multisystemic Approach.NeuroSci · 2025Review
- Biological Susceptibility of Patients with Schizophrenia to Metabolic Syndrome: A Review.Alpha psychiatry · 2025Review
- Investigating the association of the plasma lipidomic profile with cognitive performance and genetic risk in the PsyCourse study.Translational psychiatry · 2025Article
- Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial.Frontiers in endocrinology · 2025Article
- Phenome-wide investigation of bidirectional causal relationships between major depressive disorder and common human diseases.Translational psychiatry · 2024Article
- Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies.Annals of general psychiatry · 2024Article
- Designing and implementing a physical exercise intervention for people with first episode psychosis using experience-based co-design: A pilot study from Chennai, India.Asian journal of psychiatry · 2024Article
- Systemic inflammation, oxidative damage and neurocognition predict telomere length in a transdiagnostic sample stratified by global DNA methylation levels.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Schizophrenia (SCZ) and major depressive disorder (MDD) in treatment-naive patients are associated with increased risk for type 2 diabetes (T2D) and metabolic syndrome (MetS). SCZ, MDD, T2D, and MetS are often comorbid and their comorbidity increases cardiovascular risk: Some risk genes are likely co-shared by them. For instance, transcription factor 7-like 2 (TCF7L2) and proteasome 26S subunit, non-ATPase 9 (PSMD9) are two genes independently reported as contributing to T2D and SCZ, and PSMD9 to MDD as well. However, there are scarce data on the shared genetic risk among SCZ, MDD, T2D, and/or MetS. Here, we briefly describe T2D, MetS, SCZ, and MDD and their genetic architecture. Next, we report separately about the comorbidity of SCZ and MDD with T2D and MetS, and their respective genetic overlap. We propose a novel hypothesis that genes of the prolactin (PRL)-pathway may be implicated in the comorbidity of these disorders. The inherited predisposition of patients with SCZ and MDD to psychoneuroendocrine dysfunction may confer increased risk of T2D and MetS. We illustrate a strategy to identify risk variants in each disorder and in their comorbid psychoneuroendocrine and mental-metabolic dysfunctions, advocating for studies of genetically homogeneous and phenotype-rich families. The results will guide future studies of the shared predisposition and molecular genetics of new homogeneous endophenotypes of SCZ, MDD, and metabolic impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.